Medicis Pharmaceutical Corp. (MRX) Reports In-Line Q2 EPS of 64c
Medicis Pharmaceutical Corp. (NYSE: MRX) reported Q2 EPS of $0.64, in-line with the analyst estimate of $0.64. Revenue for the quarter came in at $190.8 million versus the consensus estimate of $188.79 million.